BRD8 Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

BRD8 Polyklonal Antikörper für WB, IF/ICC, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IF/ICC, ELISA

Konjugation

Unkonjugiert

Publikationen

2

Kat-Nr. : 10476-1-AP

Synonyme

TrCP120, SMAP2, SMAP, p120, Bromodomain-containing protein 8

---

Galerie der Validierungsdaten

• 

  WB analysis of HeLa using 10476-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 10476-1-AP (BRD8 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 10476-1-AP

  WB result of BRD8 antibody (10476-1-AP; 1:2000; incubated at room temperature for 1.5 hours) with sh-Control and sh-BRD8 transfected HeLa cells.

• 

  WB analysis using 10476-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10476-1-AP (BRD8 antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human brain using 10476-1-AP

  human brain tissue were subjected to SDS PAGE followed by western blot with 10476-1-AP (BRD8 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human brain using 10476-1-AP

  human brain tissue were subjected to SDS PAGE followed by western blot with 10476-1-AP (BRD8 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  IF Staining of HeLa using 10476-1-AP

  Immunofluorescent analysis of (4% PFA) fixed HeLa cells using BRD8 antibody (10476-1-AP) at dilution of 1:400 and Multi-rAb CoraLite ® Plus 488-Goat Anti-Rabbit Recombinant Secondary Antibody (H+L) (RGAR002).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HeLa-Zellen, HuH-7-Zellen, humanes Hirngewebe
• Erfolgreiche Detektion in IF/ICC: HeLa-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:6000
• Immunfluoreszenz (IF)/ICC: IF/ICC : 1:200-1:800

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• WB: See 2 publications below

Produktinformation

10476-1-AP bindet in WB, IF/ICC, ELISA BRD8 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: BRD8 fusion protein Ag0790
• Vollständiger Name: bromodomain containing 8
• Berechnetes Molekulargewicht: 120 kDa
• Beobachtetes Molekulargewicht: 120-170 kDa
• GenBank-Zugangsnummer: BC008039
• Gene symbol: BRD8
• Gene ID (NCBI): 10902
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

BRD8 is one of the bromodomain-containing proteins, which is an acetylated lysine-binding domain and thought to be involved in regulation of protein acetylation and/or HAT (histone acetyl transferase) activity [PMID: 12963728]. Interestingly, in the breast cancer cells we detected the 170 kDa endogenous BRD8 protein, which was larger than its calculated 135 kDa molecular weight (MW) from its a.a. residues. The study found that with an anti‐HA tag antibody, we validated the expression of HA‐tagged full‐length BRD8 and four different BRD8 fragments expressed in HEK293T cells. The apparent MWs of these BRD8 full‐length and fragment proteins were also larger than their calculated MWs based on their a.a. residues. (PMID: 37680145)

Publikationen

Species	Application	Title
human	WB	Nature; ANP32E is a histone chaperone that removes H2A.Z from chromatin.; Authors - Arnaud Obri
human	WB	Arch Biochem Biophys; BRD8, which is negatively regulated by miR-876-3p, promotes the proliferation and apoptosis resistance of hepatocellular carcinoma cells via KAT5.; Authors - Zhaoxiang Yu